NCT04018950View on ClinicalTrials.gov

Study to Determine the Excretion and Metabolism of 14C-ETX2514 Administered Intravenously in Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

June 21, 2019

Primary Completion Date

July 26, 2019

Study Completion Date

July 26, 2019

Conditions
Acinetobacter Baumannii-calcoaceticus Complex Infections
Interventions
DRUG

ETX2514

intravenous infusion

DRUG

14C-ETX2514

intravenous infusion

Trial Locations (1)

21201

Pharmaron Clinical Pharmacology Center, Baltimore

Sponsors
All Listed Sponsors
lead

Entasis Therapeutics

INDUSTRY

NCT04018950 - Study to Determine the Excretion and Metabolism of 14C-ETX2514 Administered Intravenously in Healthy Male Subjects | Biotech Hunter | Biotech Hunter